ivonescimab
-
One good drug can change fate! Summit’s stock price soars by 119%, with its market value increasing more than a hundredfold
For upcoming reports, please follow DrugTimes
-
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC
Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Tri…
